Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Scientists Give Leadership High Marks, But Some Worry About Industry Influence

Executive Summary

A Union of Concerned Scientists' survey finds 65% of 354 respondents believe their direct supervisors back them on politically contentious positions; US FDA Commissioner Scott Gottlieb gets glowing reviews.

You may also be interested in...



Molecular Dx Exec Named New US FDA Diagnostics Chief

Timothy Stenzel brings experience developing and commercializing new molecular diagnostics, including companion tests, and running a clinical laboratory to his new role as director of US FDA's Office of In Vitro Diagnostics and Radiological Health.

US FDA Hiring For Senior Staff Vacancies Boosted By Cures Act, Pilot Program – Gottlieb

Recent departures are 'business as usual' at the agency, Commissioner says. 

FDA's Hiring Advantage: Scores In Best Places To Work Survey Continue To Rise

US agency ranks 32nd out of 150 agency subcomponents in annual survey of employees.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT123168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel